2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

11:00AM-12:30PM: Abstract Number: 2753

Brain Functional Connectivity Features of Pain Centralisation Relate to Degree of ‘Fibromyalgianess’ in Rheumatoid Arthritis

Plenary Session III

11:00AM-12:30PM: Abstract Number: 2755

Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty

Plenary Session III

11:00AM-12:30PM: Abstract Number: 2754

Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial

Plenary Session III

11:00AM-12:30PM: Abstract Number: 2756

Effect of Baseline and Change in Effusion-Synovitis on Cartilage Damage over 18 Months in Patients with Osteoarthritis and Meniscal Tear

Plenary Session III

11:00AM-12:30PM: Abstract Number: 2757

Kidney and Skin Single-Cell RNA Sequencing in Lupus Nephritis Provides Mechanistic Insights and Novel Potential Biomarkers

Plenary Session III

11:00AM-12:30PM: Abstract Number: 2758

Response to JAK1/2 Inhibition with Baricitinib in “Candle”, “Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN-Mediated Autoinflammatory Diseases

Plenary Session III

2:30PM-4:00PM: Abstract Number: 2796

A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2798

A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy

2:30PM-4:00PM: Abstract Number: 2774

Activation of a Cytosolic DNA Sensor Pathway in the Etiopathogenesis of Sjögren’s Syndrome

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2767

Active Yet Sedentary: The Association of Moderate to Vigorous Physical Activity and Sedentary Behavior with Incident Functional Limitation in Knee OA

ARHP Rehabilitation Science

2:30PM-4:00PM: Abstract Number: 2761

Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2760

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2794

Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2784

Are We over-Testing for Liver Enzyme Abnormalities in Rheumatoid Arthritis Patients Prescribed Methotrexate?

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2781

Assessing RA Disease Activity with Promis Measures Using Smartphone Technology

Patient Outcomes, Preferences, and Attitudes II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].